Navigation Links
Mindray Appoints Mr. Ronald Ede as Chief Financial Officer
Date:3/4/2009

su has been instrumental in positioning Mindray as an internationally recognized, value-driven medical device company," said Mr. Xu Hang, Mindray's Chairman and co-Chief Executive Officer. "On behalf of the board of directors and Mindray, I want to personally thank Joyce for her tremendous contributions to the company over the past several years. We are fortunate to have Joyce remain with us as a director, and we will continue to look to her for guidance and leadership."

Staying on as a director, Ms. Hsu will replace Mr. Ede on the compensation committee and the nominations and corporate governance committee of Mindray's board, effective immediately. Mr. Ede continues to serve on Mindray's board of directors but does not serve on any of the board's committees. Ms. Hsu will immediately begin working closely with Mr. Ede in the transition period between now and May 1, 2009, when Mr. Ede takes on the CFO role. Ms. Hsu will remain available in an advisory capacity after Mr. Ede takes the CFO position.

About Mindray

Mindray is a leading developer, manufacturer and marketer of medical devices worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring & life support products, in-vitro diagnostic products and medical imaging systems. Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters in Mahwah, New Jersey. Mindray also has another 12 international sales and service offices in Amsterdam, Frankfurt, Istanbul, London, Mexico City, Moscow, Mumbai, Paris, Sao Paolo, Seattle, Toronto and Vancouver. For more information, please visit http://www.mindray.com .


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mindray Announces 2008 Fourth Quarter and Full Year Results
2. Mindray Medical International Announces Second Quarter 2008 Results
3. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
4. Mindray Medical International Announces First Quarter 2008 Results
5. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
6. Mindray Medical International Announces Third Quarter 2007 Results
7. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
8. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
9. Savara Expands Board of Directors, Appoints Three New Members
10. Informed Medical Communications Appoints New Senior Manager, Strategic Operations
11. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
(Date:12/15/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive six-month interim ... to evaluate once-weekly TransCon Growth Hormone in children ... analysis consists of 25 patients, representing approximately 50% ... completing all six months of treatment. ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Biofuels Key Issues in 2008, NEW YORK, Dec. ... and developments in biofuels are some of the issues,addressed ... The Outlook is produced annually by the Food ... analysis covering all of,the major sectors throughout the food ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient ... investigating the intratumoural,delivery of REOLYSIN(R) in combination ... A total of 23 patients received a ... REOLYSIN(R) at escalating dosages up to a,maximum ...
... Pharmaceuticals,LLC, a clinical stage drug-development company commercializing,first-in-class ... that enhances,oxygen diffusion, today announced that one ... recently recognized as a co-inventor of the ... alpha), a,erythropoiesis stimulating agent (US Patent No. ...
Cached Biology Technology:Rabobank Releases Annual North American Food & Agribusiness Outlook 2Rabobank Releases Annual North American Food & Agribusiness Outlook 3Rabobank Releases Annual North American Food & Agribusiness Outlook 4Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial 2Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics 2
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... is a metaphorical example of the perfect invasion by a ... a deserted island in the Galapagos Archipelago, the first cancer ... through many generations to establish itself as an invader of ... like any newly stabilized species in different ecological niches, cancer ...
... at Pacific Northwest National Laboratory have developed a ... meet or exceed current and emerging defense and ... Quartz Laser Photo-Acoustic Sensing, or "QPAS," is now ... PNNL, a Department of Energy national laboratory, has ...
... blood pressure measuring above the normal range (less than 120/80 ... strokes, or kidney disease. Lifestyle changes are the first-stage treatment ... , Many patients with high blood ... In so doing, many have consumed danshen, a Chinese herb ...
Cached Biology News:Cancer that colonizes our bodies 2New sensor detects gaseous chemical weapon surrogates in 45 seconds 2Active ingredient in common Chinese herb shown to reduce hypertension 2
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
SAPK/JNK Antibody...
Biology Products: